HC Wainwright Forecasts Strong Price Appreciation for Unicycive Therapeutics (NASDAQ:UNCY) Stock

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) had its price objective lifted by equities research analysts at HC Wainwright from $4.00 to $7.50 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright also issued estimates for Unicycive Therapeutics' Q1 2025 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.35) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at $0.92 EPS, FY2026 earnings at $0.92 EPS, FY2027 earnings at $1.98 EPS, FY2027 earnings at $1.98 EPS, FY2028 earnings at $1.19 EPS and FY2029 earnings at $1.34 EPS.

Unicycive Therapeutics Trading Down 12.6 %

Shares of Unicycive Therapeutics stock traded down $0.07 during trading hours on Tuesday, reaching $0.52. The stock had a trading volume of 1,487,238 shares, compared to its average volume of 1,429,010. Unicycive Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.49. The firm has a market capitalization of $53.55 million, a PE ratio of -0.53 and a beta of 2.26. The stock's 50 day moving average is $0.58 and its 200 day moving average is $0.57.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13). As a group, sell-side analysts predict that Unicycive Therapeutics will post -0.23 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of UNCY. Northern Trust Corp raised its holdings in shares of Unicycive Therapeutics by 142.4% during the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after acquiring an additional 34,183 shares during the last quarter. XTX Topco Ltd acquired a new position in Unicycive Therapeutics in the 3rd quarter valued at $29,000. Virtu Financial LLC lifted its holdings in Unicycive Therapeutics by 566.8% in the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock valued at $30,000 after purchasing an additional 62,881 shares in the last quarter. Geode Capital Management LLC boosted its stake in Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after purchasing an additional 122,089 shares during the last quarter. Finally, Acuta Capital Partners LLC grew its holdings in shares of Unicycive Therapeutics by 16.4% during the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock worth $1,829,000 after buying an additional 323,801 shares in the last quarter. Institutional investors and hedge funds own 40.42% of the company's stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.